GlobeNewswire·May 26, 2026, 4:05 PM ET

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Assembly Biosciences closed its underwritten registered offering of 3,924,624 shares of common stock at $26.50 per share, including the full exercise of the underwriters' option for 566,040 additional shares.
The company also sold pre-funded warrants to an existing investor for up to 415,000 shares at $26.499 per warrant, with an exercise price of $0.001 per share.
Aggregate gross proceeds from the offering totaled approximately $115.0 million before deducting underwriting discounts, commissions, & other expenses.
Net proceeds will be used to fund clinical development of pipeline candidates & for general corporate purposes.
Guggenheim Securities & UBS Investment Bank served as joint book-running managers, Mizuho acted as a book-running manager, & H.C. Wainwright & Co. served as lead manager.
A shelf registration statement for the securities was declared effective by the SEC on March 27, 2026.
Assembly Biosciences is focused on developing therapeutics for serious viral & liver diseases, including HDV, HBV, herpesvirus, & cholestatic liver diseases.